Bucindolol

Discontinued Product

Bucindolol (Cat. No. 2658) has been withdrawn from sale for commercial reasons.
Cat.No. 2658 - Bucindolol | C22H25N3O2 | CAS No. 71119-11-4
Description: β1 and β2 antagonist
Alternative Names: MJ 13105
Chemical Name: 2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Non-selective β-adrenoceptor antagonist with additional α1-adrenoceptor blocking activity. Ki values are 1.61, 1.20 and 68.9 nM for β1-, β2- and α1-adrenoceptors respectively. Also acts as a weak 5-HT2A/2B antagonist. Displays vasodilatory and antihypertensive actions.

Technical Data

M. Wt 363.45
Formula C22H25N3O2
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 71119-11-4
Smiles CC(NCC(O)COC3=C(C#N)C=CC=C3)(C)CC1=CNC2=C1C=CC=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References

References are publications that support the biological activity of the product.

Watts et al (2000) Interaction of the [beta] adrenergic receptor antagonist bucindolol with serotonergic receptors. J.Cardiovasc.Pharmacol. 35 29 PMID: 10630730

Ponicke et al (2002) Differential effects of bucindolol and carvedilol on noradrenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats. J.Pharmacol.Exp.Ther. 301 71 PMID: 11907159

Marwood and Stokes (1985) Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J.Cardiovasc.Pharmacol. 7 S67

View Related Products by Product Action

View all Non-selective Adrenergic β Receptor Antagonists

Keywords: Bucindolol, Bucindolol supplier, α1-adrenoceptor, beta1-adrenoceptor, b1-adrenoceptor, b1-adrenergic, β1-Adrenergic, beta1-Adrenergic, α2-adrenoceptor, beta2-adrenoceptor, β2-adrenergic, α2-adrenergic, beta2-adrenergic, b2-adrenoceptor, antagonists, Receptors, Non-Selective, MJ, 13105, Non-selective, Adrenergic, Beta, 2658, Tocris Bioscience

Citations for Bucindolol

Citations are publications that use Tocris products.

Currently there are no citations for Bucindolol.

Reviews for Bucindolol

There are currently no reviews for this product. Be the first to review Bucindolol and earn rewards!

Have you used Bucindolol?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.